Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
EV to Sales: Premium Valuation
Trending higher, above historical average, strong compound growth.
Left:
||||
Enterprise value to sales ratio
Latest
92.68
↑ 172% above average
Average (9y)
34.08
Historical baseline
Range
High:92.68
Low:1.43
CAGR
+59.0%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 92.68 | +323.1% |
| 2023 | 21.90 | +156.3% |
| 2022 | 8.55 | -70.9% |
| 2021 | 29.39 | -15.2% |
| 2020 | 34.64 | +59.8% |
| 2019 | 21.67 | -26.9% |
| 2018 | 29.64 | +35.6% |
| 2017 | 21.86 | -72.3% |
| 2016 | 79.05 | +5444.4% |
| 2015 | 1.43 | - |